MicroRNAs are small non-coding RNAs that control gene expression either by degradation or translational silencing of
mRNA. These small RNAs have been shown to contribute to the control of many biological key processes like cell signaling,
proliferation, differentiation, apoptosis. Accordingly, their dysregulation has been linked to the pathogenesis of several diseases.
Recently, it has been shown that microRNAs cannot only be detected in tissue samples but also in at least 12 different human body
fluids including urine. This qualifies microRNAs as high potential non-invasive biomarkers.
During the past 3 years we have analyzed more than 4000 whole blood samples in hypothesis-free microRNA screenings
collaborating with numerous clinical centers of excellence. We have successfully discovered non-invasive microRNA biomarker
signatures from more than 40 cancers, inflammatory, immune and infectious diseases. Results of these studies have been
published in 18 peer reviewed journal articles (including Nature Methods, Sept 2011, ?Toward the blood-borne miRNome of
human diseases? )
Most of our discovered signatures have diagnostic, differential diagnostic or prognostic value. We will present recent
evidence on the high potential of microRNAs as predictive biomarker for non-invasive surveillance of drug responses, therapy
monitoring and patient stratification. Preliminary results from a longitudinal and cross-sectional study show that a microRNA
signature from blood is correlating with positive therapy response and the signature of treated responding patients correlates well
with the signature of an indepedent healthy control group.
Case studies will be presented to demonstrate the potential of microRNA biomarkers as non-invasive biomarkers for
diagnosis, therapy monitoring and drug response.
Dr. Matthias Scheffler | VP Business Development & Sales, Comprehensive Biomarker Center GmbH Heidelberg, Germany. Matthias Scheffler
serves as Vice President of Business Development & Sales of the Comprehensive Biomarker Center GmbH. He coordinates all sales activities for
Comprehensive Biomarker Center GmbH products and services. In his former position Dr. Scheffler served as VP Sales Europe & Asia for febit
biomed GmbH, a biotechnology company offering proprietary microarray products and services. He acquired strong knowledge of febit?s products
and all manufacturing processes from his previous position as the companies Vice President of Operations, being responsible for instrument
manufacturing, production of febit Biochips and related consumables as well as for supply chain management. Dr. Scheffler joined febit in October
1999 as Development Scientist responsible for Biochip Development. He was then promoted to a Team Manager. Upon restructuring in 2005
he stayed with the company as a co-founder. Transitioning to Operations he joined the Senior Management in 2006, before Having successfully
ompleted his studies of Chemistry at the Universities of Ulm and Freiburg, Dr. Scheffler received his Ph.D. in the field of nucleic acid chemistry at
the University of Bochum.
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals